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Abstract
Background: By attenuating the systemic inflammatory response to major surgery, the pre-operative
administration of steroids may reduce the incidence of complications.
Methods: A systematic review was conducted to identify randomized controlled trials (RCT) comparing
pre-operative steroid administration with placebo during a liver resection. Meta-analyses were performed.
Results: Five RCTs were identified including a total of 379 patients. Pre-operative steroids were asso-
ciated with statistically significant reductions in the levels of serum bilirubin and interleukin 6 (IL-6) on
post-operative day one. There was a trend towards a lower incidence of post-operative complications
and prothrombin time (PT), but this did not reach statistical significance.
Conclusion: Pre-operative steroids may be associated with a clinically significant benefit in liver
resection.
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Introduction
Major surgery is associated with an acute systemic inflammatory
response mediated by endogenously generated cytokines and free
radicals.1,2 When excessive or uncontrolled this may lead to the
systemic inflammatory response syndrome (SIRS).3 The degree of
SIRS after surgery may correlate with post-operative morbidity,
mortality and a delayed return to function.4 There has been inter-
est in how this response may be modified in other major surgical
procedures.5,6 A liver resection is a procedure which may be asso-
ciated with a marked cytokine response, that may be potentiated
by the ischaemia–reperfusion injury caused by portal triad clamp-
ing and other methods of vascular control used in liver surgery.7–9
Steroids are known to have significant analgesic10 and
antiemetic11–13 properties, but their immunological and anti-
inflammatory effects may improve the outcomes of a liver resec-
tion. It has been postulated that the peri-operative use of steroids
may decrease the cytokine response and thus improve surgical
outcomes.14 The potential for the benefit of the use of steroids in
liver surgery is supported by experimental studies.15–17 Neverthe-
less, the utility of pre-operative steroid use in clinical liver resec-
tion remains controversial and their use is not a widespread
practice. The aim of this systematic review and meta-analysis was
to critically appraise the available evidence, with particular refer-
ence to randomized controlled trials (RCT).
Methods
A systematic literature search was independently conducted by
two authors (A.J.R. and V.L.). The following electronic databases
were searched: Medline (1950–2012), Embase (1974–2012),
Cochrane Controlled trials Register and the science citation index.
Combinations of medical subject headings (MeSH) as well as key
words were used including the following: glucocorticoids, pred-
nisone, methylprednisone, dexamethasone, steroids, predniso$,
methylprednis$, liver surgery, hepatic resection, liver resection,
hemihepatectomy and hepatectomy.
The literature search was not restricted by language or year of
publication but was restricted to human trials. The last search was
done on the 26 March 2012. A manual search was done of all the
relevant articles and independent experts were contacted to
retrieve other relevant articles.
Study selection and primary endpoints
Only RCTs comparing peri-operative steroid administration with
placebo were included in the review. Studies describing paediatric
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liver resections, cadaveric liver transplantation or laparoscopic
liver resection were excluded, as were animal studies. The primary
end points analysed were in-hospital mortality and complications.
The secondary end points analysed were prothrombin time (PT),
level of serum bilirubin and level of serum interleukin 6 (IL-6) on
the first post-operative day. Those studies with insufficient data
relating to the defined primary and secondary outcomes were
excluded. The total number of complications was recorded as
reported in the original papers and comprised myocardial infarc-
tion, chest infection, bile leak, intra-abdominal collections or pul-
monary embolus. The recording was in accordance with the
PRISMA criteria.18 Two reviewers independently performed
article selection and these were reviewed by the third author (J.L.).
The methodological quality of studies was assessed using the
Cochrane Collaboration’s tool for assessing the risk of bias19 using
the following criteria: adequate sequence generation, allocation
concealment, blinding, addressing of incomplete data and
whether the article appeared to be free of selective reporting and
other biases.
Statistical analysis
Meta-analyses were performed using Revman 5.1 (Review
manager version 5.1; Cochrane collaboration 2011). Primary out-
comes were expressed as an odds ratio (OR) with 95% confidence
intervals (CIs) derived by the mean difference. A random effects
model was used for the analysis. The Mantel–Haenzsel method
was used for dichotomous outcomes and the inverse variance
method was used for continuous outcomes. Heterogeneity was
assessed using Cochran’s Q statistic and an I2 statistic, where
values of 25% or less were considered to indicate low heterogene-
ity and values of 75% or more were taken to indicate high hetero-
geneity.20 Forrest plots were constructed with P-values of less than
0.2 considered to be statistically significant.
Results
Description of studies
Five studies met the predefined inclusion criteria, were included in
the meta-analysis and are summarized in Table 1.21–25 The search
strategy results are shown in Fig. 1. One group published three
papers covering the same group of patients. Two of these studies
were rejected26,27 and only one study was included.23 Another study
that focused mainly on renal function after cadaveric liver trans-
plantation was excluded.28 Of the five included studies, two came
from Japan, two from Italy and one from Germany. There were a
total of 379 patients, with 190 patients in the pre-operative steroid
group and 189 in the placebo group.More than half of the patients
came from one study. There was no mortality reported in any of
the analysed papers. Only one study used a classification of com-
plication severity,25 albeit not standardized. Standardized defini-
tions of complications in liver surgery29–31 or of complication
severity32 were not used in any study. The characteristics of the
procedures (extent of resection, method of transaction, use, type
and duration of vascular control) and patients are summarized in
Table 2. The indications for liver resection are set out in Table 3.
Study quality
There was statistically significant heterogeneity observed in the
analysis of length of stay (I2 = 77%), level of bilirubin on post-
operative day 1 (I2 = 85%), PT on post-operative day 1 (I2 = 76%)
and IL-6 on post-operative day 1 (I2 = 93%) but not with respect
to complications (I2 = 0%). Given the small number of studies,
funnel plot analysis could not be reliably interpreted and was not
performed. A risk of bias diagram is shown in Fig. 2. Only one
study reported on all the parameters analysed.23 No study was
deficient in reporting on more than two parameters.
Primary study endpoints
Data were available for all studies. There was nomortality in either
group. There was a trend towards a reduction in the incidence
of post-operative complications with steroid administration
(Fig. 3a), but this did not reach statistical significance (P = 0.09,
OR = 0.68 95% CI 0.44 to 1.06).
Secondary study endpoints
Data were available from all five studies with regard to length of
stay (Fig. 3b), post-operative serum bilirubin (Fig. 3c) and serum
Table 1 Summary of randomized controlled trials analysed
First author Institution Year Steroids administration regime Steroids group
number of patients
Placebo group
number of patients
Total number
of patients
Yamashita Fukuoka, Japan 2001 MP 500 mg 2 h prior to surgery 17 16 33
Muratore Torino, Italy 2003 MP 30 mg/kg 30 min prior to surgery 25 28 53
Aldrighetti Milan, Italy 2006 MP 500 mg prior to induction of
anaesthesia
36 37 73
Schmidt Berlin, Germany 2007 MP 30 mg/kg 90 min prior to surgery 10 10 20
Hayashi Tokyo, Japan 2011 MP 500 mg prior to hepatic pedicle
clamping
300 mg on post-operative day 1
200 mg on post-operative day 2
100 mg on post-operative day 3
102 98 200
190 189 379
MP, Methylprednisolone.
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Figure 1 Flow chart showing the search strategy used to identify studies. RCT, randomized controlled trial
Table 2 Summary of characteristics of procedures and patients included in the studies
First author Group Major
resectiona
Resection
techniqueb
Vascular controlb Ischaemic time
(mins)
Cirrhosis
Yamashita Steroids 5/17 NS PTC or HVE with TVE NS NS
Placebo 6/16 NS NS
Muratore Steroids 13/25 KC or UD PTC (continuous) 41.4 (15.9)c 7/25
Placebo 15/28 37.3 (17.8)c 12/28
Aldrighetti Steroids 26/36 UD or US PTC (intermittent) 52.4 (20–89)d 14/36
Placebo 27/37 48 (20–78)d 12/36
Schmidt Steroids 6/10 UD None used NA NS
Placebo 5/10 NA NS
Hayashi Steroids 11/102 NS PTC (intermittent) 72 (0–247)d NS
Placebo 15/98 60 (0–203)d NS
aResection of three or more adjacent segments.
bThe same method of vascular control used in both groups.
cMean (SD).
dMedian (range).
PTC, portal triad clamping; HVE, hemi-hepatic vascular occlusion; TVE, total vascular exclusion; NA, not applicable; NS, not stated; UD, ultrasonic
dissector; KC, Kelly-clysis; US, ultrasonic shears.
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PT (Fig. 3d). No effect was observed with respect to the length
of stay (P = 0.5, OR = -0.99 95% CI -3.86 to 1.89). There was
a statistically significant reduction in post-operative serum
bilirubin associated with the use of steroids (P = 0.05, OR -0.43
95% CI -1.04 to -0.015). Steroid treatment was associated with a
trend towards, although not statistically significant, reduced post-
operative PT (P = 0.1, OR -0.04 95% CI -0.1 to 0.01). Data were
available in four of the studies pertaining to post-operative serum
IL-6 (Fig. 3e). There was a significant reduction in serum IL-6 in
association with steroid administration (P = 0.01, OR -46.4 95%
CI -83.4 to -9.39).
Discussion
This is the first systematic review of the use of pre-operative
steroids focused exclusively on studies of liver resection. There
were five RCT identified. Meta-analysis demonstrated reductions
in the serum bilirubin and IL-6 on post-operative day one. There
was a trend towards a reduction in the incidence of post-
operative complications and PT, although this was not statisti-
cally significant. No effect was observed with respect to the
length of stay.
One previous systematic review addressed different major
abdominal procedures and found a decrease in length of stay and
complications in those patients who were treated with pre-
operative steroids.33 Similarly, there has been one systematic
review of the use of pre-operative steroids in oesophageal resec-
tion which suggested a similar benefit, but the authors did point
out that the quality of the included trials was poor and this tem-
pered the firmness with which conclusions could be drawn.34
Additionally, there has been one systematic review of pharmaco-
logical interventions to reduce ischaemia–reperfusion injury in
elective liver resection with vascular occlusion.35 This review sug-
gested that pre-operative steroids may attenuate such an injury.
Inflammation is necessary for tissue healing after surgery, but it
is thought that an excessive response may contribute to post-
operative morbidity, mortality and may delay post-operative
recovery.2,36–38 Additionally, an excessive inflammatory response
may lead to SIRS and resultant multi-organ dysfunction syn-
drome.39,40 The hepatic acute-phase response41,42 is a physiological
process believed to be focused on the restoration of homeostasis.
This response is mainly modulated by inflammatory cytokines of
which the most important appear to be IL-6, IL-8 and tumour
necrosis factor alpha (TNF-a).4,27,43,44 This systematic review
included four studies in which IL-6 was measured. IL-6 was sig-
nificantly decreased on post-operative day 1 after treatment with
steroids.
There may be a relationship between the use of occlusive vas-
cular control (such as portal triad clamping), extent of resection
and the acute phase response to liver resection. Although the first
animal studies showing a protective effect of steroids on liver
ischaemia appeared more than 30 years ago,45 the mechanism is
still unclear. However, it may be related to suppression of inflam-
matory cytokines, increased tissue blood flow, stabilization of cell
membranes and decreased lysosomal protease release.21,46–50 The
level of serum bilirubin on post operative day 1 does have a
prognostic value in terms of clinical outcome and in particular the
occurrence of liver failure.51,52 Morbidity is related to the extent of
resection as well as the ischaemic period. It may be that only a
subset of high-risk patients (having a major resection or with
prolonged vascular occlusion) are deriving benefit from pre-
operative steroid administration. However, given the relatively
Table 3 Indications for liver resection
Steroid group Placebo group
Hepatocellular carcinoma 92 87
Metastatic colorectal cancer 47 43
Cholangiocarcinoma 10 12
Living-related donor 4 4
Other 12 15
Figure 2 Risk of bias summary: review authors' judgements about
each risk of bias item for each included study
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Figure 3 Forest plots illustrating meta-analysis of outcomes in patients undergoing a liver resection with pre-operative steroid administration
(steroids) or placebo (control). The outcomes analysed were post-operative complications (a), length of stay (b), serum bilirubin (c),
prothrombin time (d) and IL-6 on postoperative day 1 (e). M-H, Mantel-Haenszel; 95% CI, 95% confidence
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small size of each of the studies in this review, there is insufficient
data to resolve this question.
Although pre-operative steroids have been recommended for
liver resection by some authors,53 there have been concerns about
the effect this may have on post-operative liver regeneration. Liver
regeneration involves a number of steps, but IL-6 and TNF-a are
important initiators of the process.54–56 As we have concluded
steroids decrease the levels of IL-6 and this could theoretically
impair liver regeneration. However, it has been shown that over-
production of IL-6 may also inhibit liver regeneration and as such,
steroid administration may have a positive effect.57 Glanemann
et al.47 showed in an animal model that steroids had no effect on
liver regeneration. It is also important to note that although we
have demonstrated that IL-6 is suppressed by steroid administra-
tion, it is not completely abolished.
Another concern with steroid administration is the potential
increased risk of infectious complications. This concern is not
substantiated by the data from this meta-analysis. Steroid admin-
istration may in fact reduce the incidence of infectious complica-
tions. The mechanisms for this apparently paradoxical effect are
not clear. However, there are a number of candidate mediators
including immunosuppressive acidic protein (IAP) and candida
antigen. IAP is a glycoprotein,58 levels of which are significantly
increased by complex surgery59 and may correlate with post-
operative infections.60 Similarly, candida antigen has been shown
to be associated with an increase in infectious complications after
a hepatectomy.61 Yamashita et al.21 showed a decrease in the levels
of these two markers with steroid administration. Human leuko-
cyte antigen (HLA)-DR expression on peripheral monocytes has
been shown to correlate with an increased risk of infection after
major surgery.62 Schmidt et al.24 found no evidence of an increase
in HLA-DR expression, or of a decrease in cellular immunity in
the group of patients treated with steroids.
In all five of the studies included in this analysis, the steroid
administration regime was slightly different. However the regimes
did have common features of pre-operative administration and
the use of methylprednisolone. Corticosteroids are known to be
less effective or indeed ineffectual if given after induction of the
inflammatory response.63,64 Given that there is a delay to the onset
of the anti-inflammatory effects of steroids for 1 to 2 h after
administration,14 all studies gave steroids pre-operatively. Methyl-
prednisolone was used in all of the studies as its anti-
inflammatory actions are five times as strong as cortisol with less
effect on electrolyte metabolism.65 The half life of methylpred-
nisolone in the blood is 2.8 h and its biological action is prolonged
for up to 36 h after administration.65 Therefore it seems reason-
able that a single dose of 500 mg would be sufficient to suppress
both early and late inflammatory effects.23,66 This variation
may account for some of the heterogeneity observed in the
meta-analysis.
There are some weaknesses in this meta-analysis. The analysis
includes only RCT; however, they are of differing quality, provid-
ing variable information about potential sources of bias. Because
the number of trials in the analysis is small, publication bias
cannot be reliably assessed. Meta-analysis is primarily a means for
addressing the issue of inadequate statistical power in studies with
a small sample size.67 Given that there was a non-statistically sig-
nificant trend in many outcomes between the steroid and placebo
groups, the question naturally arises whether this is a result of a
lack of power or could be a false-negative result owing to other
causes. There was highly significant heterogeneity in the length of
stay, bilirubin and PT on post-operative day one. This heteroge-
neity may be attributable to differences in the patients (such as
underlying liver disease), intervention (dose of steroids), opera-
tions (extent of liver resection and use of vascular occlusion),
outcome assessment and quality of reporting. This heterogeneity
may obscure an important treatment effect.
More than half of the patients came from one study where the
steroid-treated group was given larger doses and administration
was continued over a number of days. From a western perspective,
the patient cohort was different in that nearly half of the patients
were having a resection for hepatocellular carcinoma. In most
western series, the majority of patients will be having a resection
for colorectal liver metastases and there will also be confounding
issues related to chemotherapy-induced liver damage. In spite of
these weaknesses, there does seem to be a clear benefit or trend
towards a benefit in every parameter examined (except length of
stay). Although the evidence is so far insufficient to justify recom-
mending a change in routine clinical practice, there is a need for a
larger multi-centre trial to further explore this strategy.
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